Dyne Therapeutics, Inc. (DYN) shareholders
Close on Nov 16, 2026Market cap $3.12BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30,785,801 | 18.70% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 13,647,376 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| JANUS HENDERSON GROUP Ltd. | 11,997,738 | 7.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 11,489,504 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.80%) | 11,207,000 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (8.50%), Rajeev Shah (8.50%) and 1 more | 9,714,392 | 8.50% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (5.40%) | 8,908,980 | 5.40% | 13G (passive) | Mar 31, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (5.10%) | 5,218,641 | 5.10% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DYN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30,912,287 | 16.55% | $686.56M | +126,486 | 0.45% |
| BlackRock, Inc. | 12,404,330 | 6.64% | $275.50M | +704,460 | 0.00% |
| Jupiter Topco LLC | 11,997,738 | 6.42% | $266.63M | New | 0.11% |
| FMR LLC | 11,207,000 | 6.00% | $248.91M | +2,298,020 | 0.01% |
| State Street Corp | 7,458,263 | 3.99% | $165.65M | +804,517 | 0.00% |
| Orbis Allan Gray Ltd | 7,006,542 | 3.75% | $155.62M | +244,311 | 0.53% |
| Atlas Venture Life Science Advisors, LLC | 6,800,099 | 3.64% | $151.03M | −2,330,366 | 17.14% |
| Vanguard Capital Management LLC | 6,310,969 | 3.38% | $140.17M | −94,100 | 0.00% |
| TCG Crossover Management, LLC | 4,615,144 | 2.47% | $102.50M | – | 2.46% |
| Vanguard Portfolio Management LLC | 4,048,428 | 2.17% | $89.92M | −113,613 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,936,806 | 2.11% | $87.44M | +1,608,433 | 0.01% |
| Fcpm Iii Services B.V. | 3,848,256 | 2.06% | $85.47M | −796,130 | 11.39% |
| Geode Capital Management, LLC | 3,743,427 | 2.00% | $83.16M | +239,313 | 0.00% |
| Vestal Point Capital, LP | 3,375,000 | 1.81% | $74.96M | −625,000 | 1.75% |
| Orbimed Advisors LLC | 3,235,684 | 1.73% | $71.86M | +317,800 | 1.33% |
| Frazier Life Sciences Management, L.P. | 3,153,082 | 1.69% | $70.03M | – | 1.53% |
| JPMorgan Chase & Co | 3,151,656 | 1.69% | $67.15M | −101,817 | 0.00% |
| Armistice Capital, LLC | 3,087,226 | 1.65% | $68.57M | −87,884 | 0.84% |
| Perceptive Advisors LLC | 2,689,235 | 1.44% | $59.73M | −1,979,604 | 0.90% |
| Logos Global Management LP | 2,550,000 | 1.37% | $56.64M | +1,150,000 | 2.44% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 246 | 191M | 100.0% | 49 / 88 | 76 / 28 | 30M | 14M |
| Q1 2026 | 228 | 188M | 100.0% | 42 / 102 | 59 / 45 | 40M | 21M |
| Q4 2025 | 233 | 181M | 96.8% | 59 / 95 | 59 / 28 | 52M | 30M |
| Q3 2025 | 207 | 159M | 85.2% | 39 / 110 | 39 / 27 | 48M | 18M |
| Q2 2025 | 197 | 129M | 69.1% | 23 / 94 | 54 / 30 | 21M | 14M |
| Q1 2025 | 205 | 122M | 65.4% | 50 / 81 | 44 / 43 | 34M | 23M |
| Q4 2024 | 200 | 112M | 59.8% | 38 / 68 | 63 / 34 | 10M | 10M |
| Q3 2024 | 200 | 113M | 60.3% | 42 / 74 | 54 / 34 | 26M | 18M |
| Q2 2024 | 193 | 112M | 60.0% | 47 / 80 | 45 / 21 | 25M | 11M |
| Q1 2024 | 169 | 97M | 52.1% | 62 / 69 | 27 / 16 | 39M | 15M |
| Q4 2023 | 124 | 73M | 39.2% | 25 / 44 | 39 / 14 | 19M | 5M |
| Q3 2023 | 114 | 60M | 32.1% | 10 / 47 | 32 / 14 | 5M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
229 funds held DYN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DYN | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7,004,602 | 3.75% | $155.57M | 1.67% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 4,602,629 | 2.46% | $102.22M | 0.97% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,471,727 | 2.39% | $99.32M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,152,258 | 2.22% | $92.22M | 0.86% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 3,809,721 | 2.04% | $84.61M | 1.68% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,550,251 | 1.90% | $78.85M | 0.10% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 3,279,669 | 1.76% | $72.84M | 0.10% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,862,005 | 1.53% | $55.32M | 0.06% | May 31, 2026 |
| Vanguard Health Care Fund | 2,808,140 | 1.50% | $70.71M | 0.19% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 2,272,649 | 1.22% | $50.48M | 0.87% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,883,544 | 1.01% | $36.41M | 0.69% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,690,072 | 0.91% | $37.54M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,656,555 | 0.89% | $41.71M | 0.12% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 1,609,880 | 0.86% | $35.76M | 0.02% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,233,541 | 0.66% | $27.40M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John Cox | CEO & President, Director | 423,994 | 0.23% | Nov 16, 2026 |
| Douglas Kerr | Head of R&D and CMO | 167,960 | 0.09% | Nov 16, 2026 |
| Johanna Friedl-Naderer | Chief Commercial Officer | 152,666 | 0.08% | Nov 16, 2026 |
| Erick Lucera | Chief Financial Officer | 117,775 | 0.06% | Nov 16, 2026 |
| Richard William Scalzo | SVP, Head of Finance & Admin. | 122,330 | 0.07% | Mar 13, 2025 |
| Oxana Beskrovnaya | Chief Scientific Officer | 195,840 | 0.10% | Mar 13, 2025 |
| Brian S. Posner | Director | 27,000 | 0.01% | Oct 6, 2026 |
| Jason P. Rhodes | Director | 428,946 | 0.23% | Aug 17, 2026 |
| Dirk Kersten | Director | 3,592,184 | 1.92% | Jul 29, 2026 |
| Barry E. Greene | Director | – | – | Jun 23, 2026 |
| David Charles Lubner | Director | 0 | – | Jun 9, 2026 |
| Edward Hurwitz | Director | 4,614,943 | 2.47% | Jun 9, 2026 |
| Catherine Stehman-Breen | Director | 115,713 | 0.06% | Jun 9, 2026 |
| Carlo Incerti | Director | 0 | – | Jun 9, 2026 |
| Vikram Karnani | Director | – | – | Dec 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Johanna Friedl-Naderer Chief Commercial Officer | Nov 13, 2026 | Sale(10b5-1 plan) | −231 | $16.82 | $3.89K | 152,666 |
| Erick Lucera Chief Financial Officer | Nov 13, 2026 | Sale(10b5-1 plan) | −1,991 | $16.82 | $33.49K | 117,775 |
| Douglas Kerr Head of R&D and CMO | Nov 13, 2026 | Sale(10b5-1 plan) | −2,604 | $16.82 | $43.80K | 167,960 |
| John Cox CEO & President, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −5,513 | $16.82 | $92.73K | 351,994 |
| Douglas Kerr Head of R&D and CMO | Oct 20, 2026 | Award | +8,000 | – | – | 170,564 |
| Brian S. Posner Director | Oct 2, 2026 | Buy | +2,500 | $16.00 | $40.00K | 27,000 |
| Douglas Kerr Chief Medical Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −1,290 | $18.88 | $24.36K | 162,564 |
| Johanna Friedl-Naderer Chief Commercial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −185 | $18.88 | $3.49K | 152,897 |
| John Cox CEO & President, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −5,658 | $18.88 | $106.82K | 357,507 |
| Douglas Kerr Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −3,745 | $24.35 | $91.19K | 163,854 |
| Johanna Friedl-Naderer Chief Commercial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −900 | $24.35 | $21.92K | 153,082 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −322,465 | $25.00 | $8.06M | 428,946 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −478,377 | $25.00 | $11.96M | 567,358 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −1,359,674 | $25.00 | $33.99M | 2,441,454 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −63,643 | $26.20 | $1.67M | 751,411 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −94,415 | $26.20 | $2.47M | 1,045,735 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −268,354 | $26.20 | $7.03M | 3,801,128 |
| Johanna Friedl-Naderer Chief Commercial Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −226 | $26.28 | $5.94K | 153,982 |
| Douglas Kerr Chief Medical Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,556 | $26.28 | $40.89K | 167,599 |
| John Cox CEO & President, Director | Aug 13, 2026 | Sale(10b5-1 plan) | −4,986 | $26.28 | $131.03K | 363,165 |
| Erick Lucera Chief Financial Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,797 | $26.28 | $47.23K | 119,766 |
| Dirk Kersten Director | Jul 27, 2026 | Sale(10b5-1 plan) | −256,072 | $25.50 | $6.53M | 3,592,184 |
| Dirk Kersten Director | Jul 27, 2026 | Sale(10b5-1 plan) | −5,388 | $26.04 | $140.30K | 3,586,796 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −5,000 | $23.61 | $118.05K | 2,962 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −124,379 | $23.17 | $2.88M | 4,099,069 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −29,587 | $23.62 | $698.84K | 4,069,482 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −11,665 | $23.62 | $275.53K | 815,054 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −49,193 | $23.17 | $1.14M | 826,719 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −14,844 | $23.62 | $350.62K | 1,140,150 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −62,543 | $23.17 | $1.45M | 1,154,994 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −100,019 | $22.79 | $2.28M | 875,912 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −253,039 | $22.79 | $5.77M | 4,223,448 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −127,182 | $22.79 | $2.90M | 1,217,537 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −51,756 | $21.14 | $1.09M | 1,344,719 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −40,702 | $21.14 | $860.44K | 975,931 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −102,969 | $21.14 | $2.18M | 4,476,487 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −64,411 | $21.28 | $1.37M | 1,016,633 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −81,903 | $21.28 | $1.74M | 1,396,475 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −162,954 | $21.28 | $3.47M | 4,579,456 |
| Erick Lucera Chief Financial Officer | Jun 25, 2026 | Sale | −2,362 | $20.37 | $48.11K | 121,563 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −5,019 | $21.10 | $105.90K | 1,081,044 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −12,699 | $21.10 | $267.95K | 4,742,410 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −6,382 | $21.10 | $134.66K | 1,478,378 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −50,530 | $21.02 | $1.06M | 4,755,109 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −25,397 | $21.02 | $533.84K | 1,484,760 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −19,973 | $21.02 | $419.83K | 1,086,063 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −39,131 | $21.13 | $826.84K | 1,510,157 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −77,855 | $21.13 | $1.65M | 4,805,639 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −30,774 | $21.13 | $650.25K | 1,106,036 |
| Dirk Kersten Director | Jun 23, 2026 | Sale(10b5-1 plan) | −71,629 | $21.04 | $1.51M | 3,849,913 |
| Dirk Kersten Director | Jun 23, 2026 | Sale(10b5-1 plan) | −1,657 | $21.47 | $35.58K | 3,848,256 |
| Dirk Kersten Director | Jun 22, 2026 | Sale(10b5-1 plan) | −190,676 | $20.57 | $3.92M | 3,921,542 |
| Dirk Kersten Director | Jun 18, 2026 | Sale(10b5-1 plan) | −46,901 | $20.07 | $941.30K | 4,112,218 |
| Dirk Kersten Director | Jun 17, 2026 | Sale(10b5-1 plan) | −37,454 | $20.14 | $754.32K | 4,159,119 |
| Johanna Friedl-Naderer Chief Commercial Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −145 | $18.33 | $2.66K | 154,208 |
| Douglas Kerr Chief Medical Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −887 | $18.33 | $16.26K | 169,155 |
| John Cox CEO & President, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −2,683 | $18.33 | $49.18K | 368,151 |
| Brian S. Posner Director | Jun 8, 2026 | Buy | +2,000 | $16.94 | $33.88K | 24,500 |
| Brian S. Posner Director | Jun 3, 2026 | Buy | +2,500 | $17.48 | $43.70K | 22,500 |
| Brian S. Posner Director | May 26, 2026 | Buy | +2,000 | $18.21 | $36.42K | 20,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dyne Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,440 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Douglas Kerr Officer | Sep 8, 2026 | 35 | $661 | Sep 8, 2026 | Restricted Stock Units |
| John Cox Officer | Sep 8, 2026 | 5,658 | $106.84K | Sep 8, 2026 | Restricted Stock Units |
| Douglas Kerr Officer | Sep 4, 2026 | 5,000 | $121.75K | Sep 4, 2026 | Restricted Stock Units |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Aug 14, 2026 | 478,377 | $12.42M | Aug 14, 2026 | Private Placement |
| Atlas Venture Fund XI, L.P. Shareholder | Aug 14, 2026 | 1,359,674 | $35.30M | Aug 14, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Aug 14, 2026 | 322,465 | $8.37M | Aug 14, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Aug 13, 2026 | 63,643 | $1.67M | Aug 13, 2026 | Private Placement |
| Atlas Venture Fund XI, L.P. Shareholder | Aug 13, 2026 | 268,354 | $7.02M | Aug 13, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Aug 13, 2026 | 94,415 | $2.47M | Aug 13, 2026 | Private Placement |
| Douglas Kerr Officer | Aug 13, 2026 | 2,443 | $64.20K | Aug 13, 2026 | Restricted Stock Units |
| Erick Lucera Officer | Aug 13, 2026 | 1,797 | $47.23K | Aug 13, 2026 | Restricted Stock Units |
| John Cox Officer | Aug 13, 2026 | 4,986 | $131.03K | Aug 13, 2026 | Restricted Stock Units |
| ForDyne B.V. Affiliate | Jul 27, 2026 | 261,460 | $6.67M | Jul 27, 2026 | IPO Conversion of Shares |
| Atlas Venture Opportunity Fund II, L.P. Shareholder | Jul 7, 2026 | 77,387 | $1.77M | Jul 7, 2026 | Private Placement |
| Atlas Venture Fund XI, L.P. Shareholder | Jul 7, 2026 | 153,966 | $3.52M | Jul 7, 2026 | Private Placement |
See a number that looks wrong?